1. Academic Validation
  2. Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells

Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells

  • Int J Mol Sci. 2022 Sep 17;23(18):10895. doi: 10.3390/ijms231810895.
Lucia Cappabianca 1 Michela Sebastiano 1 Marianna Ruggieri 1 Maddalena Sbaffone 1 Veronica Zelli 1 Antonietta Rosella Farina 1 Andrew Reay Mackay 1
Affiliations

Affiliation

  • 1 Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Abstract

Patients with advanced neuroblastoma (NB) receive multimodal clinical therapy, including the potent anthracycline chemotherapy drug doxorubicin (Dox). The acquisition of Dox resistance, however, is a major barrier to a sustained response and leads to a poor prognosis in advanced disease states, reinforcing the need to identify and inhibit Dox resistance mechanisms. In this context, we report on the identification and inhibition of a novel Dox resistance mechanism. This mechanism is characterized by the Dox-induced activation of the oncogenic TrkAIII alternative splice variant, resulting in increased Dox resistance, and is blocked by lestaurtinib, entrectinib, and crizotinib tyrosine kinase and LY294002 IP3-K inhibitors. Using time lapse live cell imaging, conventional and co-immunoprecipitation Western blots, RT-PCR, and inhibitor studies, we report that the Dox-induced TrkAIII activation correlates with proliferation inhibition and is CDK1- and CA2+-uniporter-independent. It is mediated by ryanodine receptors; involves CA2+-dependent interactions between TrkAIII, Calmodulin and Hsp90; requires oxygen and oxidation; occurs within assembled ERGICs; and does not occur with fully spliced TrkA. The inhibitory effects of lestaurtinib, entrectinib, crizotinib, and LY294002 on the Dox-induced TrkAIII and Akt phosphorylation and resistance confirm roles for TrkAIII and IP3-K consistent with Dox-induced, TrkAIII-mediated pro-survival IP3K/Akt signaling. This mechanism has the potential to select resistant dormant TrkAIII-expressing NB cells, supporting the use of Trk inhibitors during Dox therapy in TrkAIII-expressing NBs.

Keywords

Ca2+ uniporter; Hsp90; TrkA; TrkAIII; calmodulin; cyclic hypoxia; doxorubicin; doxorubicin-resistance; neuroblastoma; ryanodine receptors; tyrosine kinase inhibitors.

Figures
Products